Assis Tália Santana Machado de, Rabello Ana, Cota Gláucia, Werneck Guilherme Loureiro, Azeredo-da-Silva André Luís Ferreira de
Centro Federal de Educação Tecnológica de Minas Gerais, Contagem, MG, Brasil.
Grupo de Pesquisa: Pesquisa Clínica e Políticas Públicas em Doenças Infecciosas e Parasitárias, Belo Horizonte, MG, Brasil.
Rev Soc Bras Med Trop. 2019 Apr 11;52:e20180272. doi: 10.1590/0037-8682-0272-2018.
Visceral leishmaniasis (VL) is fatal if not diagnosed and treated. This study aimed to estimate the cost-effectiveness of diagnostic-therapeutic alternatives for VL in Brazil.
A decision model estimated the life expectancy and costs of six diagnostic-therapeutic strategies.
IT LEISH + liposomal amphotericin B emerged the best option, presenting lower costs and higher effectiveness. DAT-LPC + liposomal amphotericin B showed an incremental cost-effectiveness ratio of US$ 326.31 per life year.
These findings indicate the feasibility of incorporating DAT and designating liposomal amphotericin B as the first-line drug for VL in Brazil.
内脏利什曼病（VL）若不进行诊断和治疗会致命。本研究旨在评估巴西针对VL的诊断 - 治疗替代方案的成本效益。
一个决策模型估算了六种诊断 - 治疗策略的预期寿命和成本。
IT LEISH + 脂质体两性霉素B成为最佳选择，成本更低且效果更佳。DAT - LPC + 脂质体两性霉素B显示每生命年的增量成本效益比为326.31美元。
这些研究结果表明在巴西纳入直接凝集试验（DAT）并指定脂质体两性霉素B作为VL一线药物的可行性。
